GBY Stock Overview
A clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Sangamo Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.28 |
| 52 Week High | US$2.85 |
| 52 Week Low | US$0.25 |
| Beta | 1.1 |
| 11 Month Change | 165.74% |
| 3 Month Change | 193.84% |
| 1 Year Change | 528.86% |
| 33 Year Change | -72.02% |
| 5 Year Change | -73.60% |
| Change since IPO | -79.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| GBY | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -12.3% | -1.9% | -0.6% |
| 1Y | 528.9% | -18.1% | 9.6% |
Return vs Industry: GBY exceeded the German Biotechs industry which returned -18.1% over the past year.
Return vs Market: GBY exceeded the German Market which returned 9.6% over the past year.
Price Volatility
| GBY volatility | |
|---|---|
| GBY Average Weekly Movement | 25.1% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: GBY's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: GBY's weekly volatility has decreased from 31% to 25% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 405 | Sandy Macrae | www.sangamo.com |
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases.
Sangamo Therapeutics, Inc. Fundamentals Summary
| GBY fundamental statistics | |
|---|---|
| Market cap | €426.64m |
| Earnings (TTM) | -€128.26m |
| Revenue (TTM) | €49.74m |
8.6x
P/S Ratio-3.3x
P/E RatioIs GBY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GBY income statement (TTM) | |
|---|---|
| Revenue | US$52.29m |
| Cost of Revenue | US$42.01m |
| Gross Profit | US$10.29m |
| Other Expenses | US$145.13m |
| Earnings | -US$134.84m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.65 |
| Gross Margin | 19.67% |
| Net Profit Margin | -257.86% |
| Debt/Equity Ratio | 0% |
How did GBY perform over the long term?
See historical performance and comparison